Ypsomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app.
The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first half of 2022.
Burgdorf, Switzerland-based Ypsomed said in a news release that the launch will start in select major countries in Europe, with other territories to follow over the course of 2022. Patients will be able to connect the MyLife YpsoPump to the MyLife CamAPS FX Android mobile app, enabling algorithm-based insulin delivery support, including bolus, from the personal smartphone.
The MyLife CamAPS FX Android app has compatibility with the Dexcom G6 CGM and represents the first CE-marked algorithm on a mobile app, Ypsomed said. The app automatically adjusts insulin delivery on the pump based on the G6’s glucose readings.
If a user overestimates or underestimates carbohydrates, the algorithm adjusts insulin delivery to prevent glucose levels from reaching levels that are too high or too low.
“We are very excited to work together with CamDiab, a trailblazer in developing interoperable loop systems,” Ypsomed CEO Simon Michel said in the release. “Together, we can make a step further in achieving our common goal, making life of people living with diabetes as easy as possible. We are looking forward to rolling out this solution in Europe over the coming months, first on Android and then also on iOS.”psomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app.
The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first half of 2022.
Burgdorf, Switzerland-based Ypsomed said in a news release that the launch will start in select major countries in Europe, with other territories to follow over the course of 2022. Patients will be able to connect the MyLife YpsoPump to the MyLife CamAPS FX Android mobile app, enabling algorithm-based insulin delivery support, including bolus, from the personal smartphone.
The MyLife CamAPS FX Android app has compatibility with the Dexcom G6 CGM and represents the first CE-marked algorithm on a mobile app, Ypsomed said. The app automatically adjusts insulin delivery on the pump based on the G6’s glucose readings.
If a user overestimates or underestimates carbohydrates, the algorithm adjusts insulin delivery to prevent glucose levels from reaching levels that are too high or too low.
“We are very excited to work together with CamDiab, a trailblazer in developing interoperable loop systems,” Ypsomed CEO Simon Michel said in the release. “Together, we can make a step further in achieving our common goal, making life of people living with diabetes as easy as possible. We are looking forward to rolling out this solution in Europe over the coming months, first on Android and then also on iOS.”psomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app.
The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first half of 2022.
Burgdorf, Switzerland-based Ypsomed said in a news release that the launch will start in select major countries in Europe, with other territories to follow over the course of 2022. Patients will be able to connect the MyLife YpsoPump to the MyLife CamAPS FX Android mobile app, enabling algorithm-based insulin delivery support, including bolus, from the personal smartphone.
The MyLife CamAPS FX Android app has compatibility with the Dexcom G6 CGM and represents the first CE-marked algorithm on a mobile app, Ypsomed said. The app automatically adjusts insulin delivery on the pump based on the G6’s glucose readings.
If a user overestimates or underestimates carbohydrates, the algorithm adjusts insulin delivery to prevent glucose levels from reaching levels that are too high or too low.
“We are very excited to work together with CamDiab, a trailblazer in developing interoperable loop systems,” Ypsomed CEO Simon Michel said in the release. “Together, we can make a step further in achieving our common goal, making life of people living with diabetes as easy as possible. We are looking forward to rolling out this solution in Europe over the coming months, first on Android and then also on iOS.”psomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app.
The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first half of 2022.
Burgdorf, Switzerland-based Ypsomed said in a news release that the launch will start in select major countries in Europe, with other territories to follow over the course of 2022. Patients will be able to connect the MyLife YpsoPump to the MyLife CamAPS FX Android mobile app, enabling algorithm-based insulin delivery support, including bolus, from the personal smartphone.
The MyLife CamAPS FX Android app has compatibility with the Dexcom G6 CGM and represents the first CE-marked algorithm on a mobile app, Ypsomed said. The app automatically adjusts insulin delivery on the pump based on the G6’s glucose readings.
If a user overestimates or underestimates carbohydrates, the algorithm adjusts insulin delivery to prevent glucose levels from reaching levels that are too high or too low.
“We are very excited to work together with CamDiab, a trailblazer in developing interoperable loop systems,” Ypsomed CEO Simon Michel said in the release. “Together, we can make a step further in achieving our common goal, making life of people living with diabetes as easy as possible. We are looking forward to rolling out this solution in Europe over the coming months, first on Android and then also on iOS.”